









































Pain Severity Correlates With Biopsy-Mediated Colonic
Afferent Activation But Not Psychological Scores in
Patients With IBS-D
Vincent Cibert-Goton, PhD1, Ching Lam, PhD, MRCP2, Melanie Lingaya, BSci2, Yirga Falcone, BSci2, John N. Wood, FMedSci, FRS3,
David C. Bulmer, PhD1,4 and Robin Spiller, MD, FRCP2
INTRODUCTION: Despite heterogeneity, an increased prevalence of psychological comorbidity and an altered
pronociceptive gut microenvironment have repeatedly emerged as causative pathophysiology in
patients with irritable bowel syndrome (IBS). Our aim was to study these phenomena by comparing gut-
related symptoms, psychological scores, and biopsy samples generated from a detailed diarrhea-
predominant IBS patient (IBS-D) cohort before their entry into a previously reported clinical trial.
METHODS: Data were generated from 42 patients with IBS-D who completed a daily 2-week bowel symptom diary,
theHospital Anxiety andDepression score, and the PatientHealthQuestionnaire-12Somatic Symptom
score and underwent unprepared flexible sigmoidoscopy. Sigmoid mucosal biopsies were separately
evaluated using immunohistochemistry and culture supernatants to determine cellularity, mediator
levels, and ability to stimulate colonic afferent activity.
RESULTS: Pain severity scores significantly correlatedwith thedaily durationof pain (r50.67,P<0.00001), urgency
(r5 0.57, P < 0.0005), and bloating (r5 0.39, P < 0.05), but not with psychological symptom scores for
anxiety, depression, or somatization. Furthermore, pain severity scores from individual patients with IBS-D
were significantly correlated (r5 0.40,P< 0.008) with stimulation of colonic afferent activationmediated
by their biopsy supernatant, but not with biopsy cell counts nor measured mediator levels.
DISCUSSION: Peripheral pronociceptive changes in the bowel seem more important than psychological factors in
determining pain severity within a tightly phenotyped cohort of patients with IBS-D. No individual
mediator was identified as the cause of this pronociceptive change, suggesting that nerve targeting
therapeutic approaches may be more successful than mediator-driven approaches for the treatment of
pain in IBS-D.
SUPPLEMENTARY MATERIAL accompanies this paper at http://links.lww.com/CTG/A510, http://links.lww.com/CTG/A509, http://links.lww.com/CTG/A508
Clinical and Translational Gastroenterology 2021;12:e00313. https://doi.org/10.14309/ctg.0000000000000313
INTRODUCTION
Chronic abdominal pain and loose stools is a debilitating con-
dition and one of the most common causes of presentation to a
gastroenterologist. After excluding inflammatory or infectious
disease, most cases are diagnosed as irritable bowel syndrome
with diarrhea (IBS-D) (1). However, the cause of the character-
istic pain remains obscure. Pain has been attributed to visceral
hypersensitivity to otherwise non-noxious stimuli, found in be-
tween 50% and 90%of patients (2). Thismay arise from a range of
abnormalities including enhanced nociception, augmented
central pain processing (3), and impaired adaptation to pain (4),
which may explain the heterogeneity of pathophysiology within
patients with irritable bowel syndrome (IBS).
Although central factors are undoubtedly important, recog-
nition that IBS could arise after acute infectious gastroenteritis, or
postinfectious IBS (PI-IBS), and the chronic changes in mucosal
cellularity and mediator content associated with PI-IBS (5,6) has
focused attention on local mucosal abnormalities. Subsequent
studies across different subgroups of patients with IBS have
broadly documented altered mast cell and endocrine cell
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numbers and mediators (7). However, such findings are not
universal and the link between mucosal changes, visceral hyper-
sensitivity, and pain symptomology in unselected patients with
IBS is variable (8–10). These disparities may be due to studying
unselected, and hence heterogeneous patients with IBS, rather
than specific subtypes.
The commonest subtype of PI-IBS is diarrhea predominant
(11), a group in whom several studies have shown alterations in
tight junctions (12) and increased permeability (13). These fea-
tures are linked to visceral hypersensivity by promoting exposure
to luminal content and local immune cell activation (14). Evi-
dence for these changes have come from biopsy studies that have
documented mast cell hyperplasia and elevated levels of media-
tors such as histamine, serotonin, and tryptase, which contribute
to activation of enteric nerves by biopsy supernatants (8,15,16). In
some studies, these changes have been shown to correlate with
pain scores or pain threshold assessed by rectal barostat, thereby
providing a link between local changes in the gut mucosa with
pain symptomology (17).
We have previously reported the results of a large proof of
concept clinical trial in patients with IBS-D (18). Nested within
the prescreening period of the trial was amechanistic study that is
reported here. We first examined the correlation between
symptoms of pain with related sensory abnormalities of urgency,
bloating, and psychological factors known to influence pain
processing (19). We then focused on the histology of the sigmoid
colonic mucosa and mediator release from incubated biopsies to
identifymediators and cell types contributing to IBS pain. Finally,
we tested the effect of sigmoid biopsy supernatant on colonic
afferent activity and correlated this with pain symptomology. We
found considerable heterogeneity in our patient group, with ev-
idence that locally generated mediators are associated with the
severity of abdominal pain, with a stronger effect than central
psychological factors in this subtype of IBS.
METHODS
Patient details
Patients with IBS-D were recruited into a multicentered, parallel
group, randomized placebo-controlled trial as previously repor-
ted (18) (ClinicalTrial.gov ISRCTN76612274). Nested within the
main trial was a mechanistic study of 42 patients who were
recruited in the Nottingham center and consented for sigmoid
biopsy before randomization. In addition to stool consistency and
frequency, other bowel-related symptoms comprising pain se-
verity and daily duration, urgency, and bloating were recorded
daily over the 14-day screening period. Pain severitywas recorded
on a 0–10 scale (05 no pain and 105 the most severe pain ever
experienced) along with daily pain duration in hours per day.
Urgency and bloating were also reported on a similar 0–10 scale,
stool frequency as bowel movements/day and stool consistency
recorded daily using the Bristol Stool Form scale. Symptoms were
recorded each evening documenting the preceding 24 hours.
All randomization patients completed the Hospital Anxiety
and Depression Scale (20) along with the Patient Health
Questionnaire-12 Somatic Symptom score, a measure of non-
gastroenterological somatic symptoms (21).
Sigmoid biopsy and assessments
After symptom screening to confirm eligibility for the trial, mu-
cosal biopsies were obtained at 30 cm from the anus during an
unprepared, unsedated flexible sigmoidoscopy in the left lateral
position. Two biopsies were taken and processed for immuno-
histochemistry and 2 were cultured to obtain supernatants. Bi-
opsy processing is detailed in the Supplemental Methods (see
Supplementary Digital Content 2, http://links.lww.com/CTG/
A510).
Two biopsies were weighed and placed into 2 mL of Hanks
balanced salt solution in a polystyrene organ culture dish and
incubated for two 30 minute periods at 37 °C, in 5% CO2. Fresh
Hankswas used for the second, 30-minute incubation period. The
supernatant collected in the first 30 minutes was used to assess
released mediators, whereas the supernatant collected in the
second 30-minute period was used for testing in colonic afferent
preparations. Supernatants were aliquoted and stored at280 oC.
Samples were transported on dry ice and aliquots were thawed on
the day of use in electrophysiological or laboratory studies.
Biopsy supernatant levels of histamine, tryptase, chymase, and
carboxypeptidase 3 (CPA3) were measured using sandwich
ELISA assays provided by the Immunopharmacology Research
Group, the University of Southampton, as described previously
(22,23). Histamine was measured using a commercially available
enzyme immunoassay kit (Neogen, Lexington, KY) as directed by
the manufacturer.
Ex-vivo recordings of colonic afferent fiber activity
Few fiber afferent activities were recorded from teased lumbar
splanchnic nerve bundles in a flat sheet colorectal preparation
(male 12-weeks old, wild-type C57BL/6 mice, or NaV1.9 2/2
mice, as previously described (24)) using suction electrodes. Re-
ceptive fields were identified and characterized based on the
criteria developed by Brierley et al. (25–27). Experiments were
only performed on the receptive fields of vascular (or serosal)
afferents.Once characterizedmechanosensitivitywas determined
by probing with 0.6 g and 1.0 g von Frey hairs (vFh). Thereafter, a
brass ring was placed around the receptive field and the in-
dwelling buffer replaced with biopsy supernatant (100 mL) for 12
minutes, and mechanosensitivity retested after removal of the
ring and supernatant. The individual single unit discharge of the
receptive field tested was discriminated using template matching
software within Spike 2 software (Cambridge Electronic Design,
Cambridge, UK) performed over the period of vFh probing.
Mechanosensitivity was determined for eachweight of vFh before
and after supernatant application, and the difference was calcu-
lated and expressed in action potentials (spikes) per second.
Chemosensitivity to biopsy supernatant was expressed as the
increase in afferent discharge over the 12-minute application
Table 1. Clinical details of patients
Mean SD N
Age 39.3 13.5 42
Gender
Male/female 15/27
HAD anxiety score 8.1 4.2 42
HAD depression score 4.8 4.4 42
PHQ-12 SS score 7.0 4.2 42
HAD5 Hospital Anxiety & Depression Scale; PHQ-12 SS5 Patient Health
Questionnaire-12 Somatic Symptom.



















period (see Supplemental Methods, Supplementary Digital
Content 2, http://links.lww.com/CTG/A510).
Power and statistical analysis
All analysis was performed using Graphpad Prism Version 7 and
above (GraphPad Software, San Diego, CA). Unless otherwise
stated, data are expressed as mean 6 SD. Normality of data was
tested by using theD’Agostino and Pearson omnibus normality
tests, and comparisons were made between parameters for
individual patients using Pearson or Spearman correlation
coefficients or between group data using a Student t-test or
Mann-WhitneyU test for parametric and nonparametric data,
respectively. Adjustments were made to significant data sets
for greater than 3 multiple comparisons using a Bonferroni
correction and false discoveries highlighted. Significance was
set at P , 0.05 or smaller.
RESULTS
Patient details
Symptom scores, psychological tests, and sigmoid biopsies were
obtained from 42 patients with IBS-D. Clinical details are shown
in Table 1.
Symptom scores
Bowel-related symptoms and their correlation with pain
severity. As required for trial entry, patients recorded frequent
loose stools (Table 1). Pain severity and bloating scores lay within
the mild-to-moderate ranges with slightly higher urgency scores.
Themean daily duration of pain experienced was 2.96 3.2 hours,
with the wide SD highlighting the heterogeneous nature of pain
experienced by patients, ranging from brief periods of pain to
more prolonged periods of pain. Pain severity was strongly cor-
relatedwith daily pain duration andurgency and to a lesser degree
with bloating and stool frequency, but not with stool consistency
(Table 1 and Figure 1).
As expected, patient symptom scores for urgency also corre-
lated significantly with stool consistency (Figure 2), but not with
stool frequency or bloating. There was no significant correlation
between symptom scores for bloating, stool frequency, or stool
consistency (Table 2).
Psychological scores and their correlationwith pain severity and
bowel-related symptoms. Anxiety, depression, and Patient
Health Questionnaire-12 Somatic Symptom scores showed sig-
nificant psychological distress with 24/42 (57%), 10/42 (24%),
and 13/42 (31%) of patients having values above the normal
cutoffs (7, 7, and 6, respectively) (20,21). However, no significant
correlation was found between these and pain severity (Table 3)
or other bowel-related symptoms (see Table S1, Supplementary
Digital content 1, http://links.lww.com/CTG/A509); although as
expected, these psychological measures were highly correlated
with each other (see Figure S1, Supplementary Digital content 3,
http://links.lww.com/CTG/A508 and Table S2, Supplementary
Digital content 1, http://links.lww.com/CTG/A509).
Effect of age and sex on bowel-related and psychological
symptom scores.No difference was observed in the magnitude of
bowel-related symptoms or psychological scores between male
and female patients. Furthermore, no correlation was observed
between any symptom score and patient age (see Table S3, Sup-
plementary Digital content 1, http://links.lww.com/CTG/A509).
Figure 1. Scatter plots of data for individual patients illustrating the correlation between pain severity scores with (a) daily pain duration and (b) symptom
scores for urgency.
Figure 2. Scatter plot of data for individual patients illustrating the correlation
between patient symptom scores for urgency and stool consistency.
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Sigmoid biopsies
Correlation of pain severity scores with biopsy mediator levels
and histology. No significant correlation was observed between
pain severity scores and biopsy supernatant levels of histamine,
tryptase, chymase, and CPA3 nor with biopsy mast cell or CD68
positive cell counts (see Table S4, Supplementary Digital content
1, http://links.lww.com/CTG/A509). Furthermore, no significant
correlation was found between biopsy mediator levels or histol-
ogy and other bowel-related symptoms (see Table S5, Supple-
mentary Digital content 1, http://links.lww.com/CTG/A509) or
psychological scores (see Table S6, Supplementary Digital con-
tent 1, http://links.lww.com/CTG/A509). It is perhaps worth
noting that there was a correlation between CPA3 and urgency
and stool consistency (Table S5, SupplementaryDigital content 1,
http://links.lww.com/CTG/A509), but after correction for mul-
tiple comparisons, this failed to reach conventional significance.
Correlation of biopsy-evoked colonic afferent activity with pain
severity scores. By contrast, application of biopsy supernatant to
the receptive field of colonic afferents produced colonic afferent
responses that correlated significantly (P , 0.008) with the se-
verity of pain experienced by the patient from which the biopsy
was obtained (Figure 3, Table 4). No correlation was found be-
tween the change in colonic afferent mechanosensitivity (0.6 g
and 1.0 g vFh) after supernatant application and pain severity
scores (Table 4).
Correlation of colonic afferent activity with biopsy mediator
levels. No significant correlation was observed between biopsy
supernatants mediator levels or biopsy histology findings and
respective magnitudes of colonic afferent activation or change in
colonic afferentmechanosensitivity (see Table S7, Supplementary
Digital content 1, http://links.lww.com/CTG/A509). This sug-
gests that multiple mediators may be responsible for the prono-
ciceptive potential of biopsy supernatants, and these mediators
may vary from patient to patient.
Effect of age and sex on biopsy responses. Furthermore, no sig-
nificant difference was found in the colonic afferent response to
the application of biopsy supernatant or subsequent change in
mechanosensitivity based on the sex of the patient fromwhich the
biopsy was taken (see Table S8, Supplementary Digital content 1,
http://links.lww.com/CTG/A509). In addition, no effect of pa-
tient sex was found on biopsymediator levels or histology, and no
correlation was found between the patients’ age and the effect of
biopsy supernatant on colonic afferent activity and mechano-
sensitivity or age and biopsy mediator release or histology (see
Table S8, Supplementary Digital content 1, http://links.lww.com/
CTG/A509).
Effect of NaV1.9 deletion on biopsy-mediated colonic afferent
responses. Given the lack of correlation of nerve response with
individualmediators in the supernatant, an alternative strategy to
the treatment of abdominal pain in IBS-D may be to target ion
channels responsible for the activation of colonic afferents by
multiple mediators. NaV1.9 is one such channel that is re-
sponsible for the sensitization of colonic afferents in response to
inflammatory and algogenic mediators (24,28) consistent with
Table 2. Bowel-related symptom scores and their correlation with pain severity
Meana SD N Pain severity
Pain severity score (0–10) 3.9 2.0 42
Daily pain duration hr/d 2.9 3.2 42 r5 0.67, P , 0.00001b
Urgency score (0–10 5.6 1.7 42 r 5 0.57, P , 0.0005c
Bloating score (0–10) 3.7 2.5 42 r5 0.40, P , 0.05c
Stool frequency BM/d 3.8 1.8 42 r 5 0.36, N.S.b
Stool consistency (BSF score) 5.4 0.7 42 r5 0.02, N.S.c
P values are adjusted for multiple comparisons using a Bonferroni correction and significance was set at P, 0.05. N.S. denotes nonsignificant comparisons with false
discoveries significant before correction highlighted by N.S.
BM, bowel Movement; BSF5 Bristol Stool Form.
aMean values averaged over 14 days from symptom diary.
bSpearman correlation coefficient (r).
cDenotes statistical comparison using Pearson.
Table 3. Correlation of patient symptom scores for urgency, bloating, stool frequency, or stool consistency
Urgency Bloating Stool frequency
Stool consistency r5 0.45, P , 0.02 a r5 2 0.10, N.S.a r 5 0 .23, N.S.b
Stool frequency r 5 0.22, N.S.b r 5 2 0.20, N.S.b —
Bloating r 5 0 .17, N.S.a —
Significant results shown in bold text.
aDenotes statistical comparison using Pearson.
bSpearman correlation coefficient (r). P values are adjusted for multiple comparisons using a Bonferroni correction, and significance was set at P , 0.05. N.S. denotes
nonsignificant comparisons.



















the observation that gain of function human NaV1.9 mutants
display episodic abdominal pain and diarrhea (28). To highlight
the therapeutic potential of NaV1.9, we also evaluated the effect of
biopsy supernatants from patients with the highest pain scores
(severity score of 5 or greater) on colonic afferent activity in tissue
from NaV1.9 2/2 mice. We demonstrated a reduced afferent
response by comparison to the responses observed when super-
natants were tested in wild type tissue (Figure 4a). Furthermore,
although colonic afferentmechanosensitivity to von Frey probing
was comparable in tissue from C7B6 mice or NaV1.9 2/2 mice
(Figure 4b), the change in mechanosensitivity after supernatant
application was also significantly reduced in tissue from
NaV1.92/2 mice (Figure 4c).
DISCUSSION
The aim of this study was to gain insight into putative mecha-
nisms of visceral pain in IBS-D. Although previous studies have
shown separately that central psychological factors such as mood
and somatization (2) and peripheral mediators (8,9) can con-
tribute to visceral pain, we have assessed these factors within a
single study. An additional strength of our study is that it has been
conducted in a single subtype of IBS, using bowel symptom scores
recorded in a daily diary rather than retrospective symptom
scores across a mixture of IBS subtypes. We have been able to
show that although variable, reported pain severity was highly
correlated with the overall daily duration of pain. Urgency, a key
feature of IBS-D, was also found to be strongly correlated with
pain severity, which is perhaps unsurprising, given that urgency is
also believed to be driven by colorectal hypersensitivity and
points toward a common pathology.
However, we found no correlation between pain severity
scores and either anxiety, depression, nor somatic sensitivity as
assessed by the PHQ-12SS. Our sample was representative of
all patients with IBS because the mean scores and the pro-
portion scoring above the upper limit of normal for anxiety
and depression were very similar to the published data from a
much larger IBS-D patient cohort (21). As a consequence, our
findings indicate that such psychological factors are not the
major determinant of pain severity in our IBS-D patient co-
hort. This does not however exclude a contribution from
psychological factors to pain in some patients with more
marked psychological disturbances who may not be selected
for clinical trials.
Our data instead point to a consistent contribution of pe-
ripheral factors to pain severity in patients with IBS-D. We ex-
amined the effect of biopsy supernatants on colonic afferent
activity in a population of lumbar splanchnic afferents classified
as vascular afferents and previously shown to display a nociceptor
phenotype (26). Recordings were performed from the lumbar
splanchnic nerve because this pathway has previously been
shown to be responsible for the transmission of pain from the
Figure 3. Effect of supernatant on afferent nerve activity a) raw trace illustrating the stimulatory effect of IBS-D biopsy supernatant on colonic afferent fiber
activity and b) scatter plot of data for individual patients illustrating the correlation between biopsymediated colonic afferent firing and pain severity scores.
Table 4. Colonic afferent activity and evoked mechanosensitivity after supernatant application and their correlation with respective pain
severity scores
Mean 6 SD
Change N Pain severityBefore After
Colonic afferent activity (spikes per
application)
116.3 6 155.1 333.0 6 333.2 216.7 6 247.7 42 r5 0.40, P , 0.008b
0.6g vFh (spikes/s) 8.4 6 5.0 9.9 6 6.2 1.56 4.3 37 r5 0.09, N.S.a
1.0g vFh (spikes/s) 9.8 6 3.0 10.5 6 4.0 0.76 3.6 34 r5 20.20, N.S.b
Significant results shown in bold text.
Distribution of the data is indicated by a for normally and b for non-normally distributed.
N.S., nonsignificant; r, Pearson correlation coefficient; vFh, von Frey hair.
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sigmoid colon (29), our site of biopsy collection. Consistent with
our hypothesis, we found a strong correlation between biopsy-
mediated colonic afferent activation and patient pain severity.
Although we found no correlation between individual biopsy
mediator levels and pain scores, we speculate that this reflects the
range of possiblemediators (e.g., histamine, serotonin, PGE2, and
tryptase) (8,9,15) that may differ from patient to patient. An al-
ternative explanation for the lack of correlation would be that
other unmeasured mediators are important, such as bile acid
derivatives, short-chain fatty acids, lipopolysaccharide, or other
microbial metabolites. One possible therapeutic approach would
be to generally suppress neural activation in the periphery while
avoiding the side effects associated with actions on higher centers
(30). To illustrate the utility of this approach, we also examined
the effect of biopsy supernatants from patients with high pain
severity scores on colonic afferent activity in tissue from
NaV1.9 2/2 mice, a channel highly expressed in colonic af-
ferents (31), and possibly implicated in IBS-D visceral noci-
ception because episodic abdominal pain and diarrhea has
been reported in the gain of function human mutants (28).
Consistent with our previous findings that colonic afferent
response to algogenic mediators and supernatants generated
from inflammatory bowel disease (IBD) patient tissue are at-
tenuated in tissue from NaV1.9 2/2 mice (24,28), we also
observed a significant reduction in the response to IBS-D bi-
opsy supernatants in NaV1.9 mouse tissue.
A further observation from this study was the significant
correlation between urgency scores and stool consistency,
suggesting that looser stools may contain mediators such as
bile acids (32) and fecal proteases (33,34) that could promote
urgency (35) by stimulating colorectal afferents (36,37). This
concept is supported by previous reports that urgency corre-
lates with fecal tryptase (38). Future studies are now warranted
to explore these possibilities and the effect of biopsy super-
natants on afferent fiber subtypes responsible for the percep-
tion of urgency such as pelvic afferents fibers within the
colorectum.
In conclusion, using a tightly defined patient group, we were
able to show a strong correlation between pain severity and the
stimulation of colonic afferent activity by biopsy supernatants,
suggesting that in this patient group, the peripheral influences are
more significant that central ones. However, we found no evi-
dence for the dominant role of any one of themediators examined
suggesting that either there is another, as yet unmeasured, me-
diator or that targeting multiple mediator pathways may be a
better strategy than targeting a single specific pathway. Future
studies should include larger panels of potential mediators that
may be present in the stool of patients with IBS.
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illustrating (a) the reduced colonic afferent response to supernatant, (b) the comparable magnitude of evoked mechanosensitivity in wild type and
NaV1.92/2 tissue before supernatant application, and (c) the lower change mechanosensitivity after supernatant application in tissue from NaV1.92/2
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Study Highlights
WHAT IS KNOWN
3 Peripheral and psychological factors contribute to
symptomology in irritable bowel syndrome (IBS).
3 Peripheral factors contribute to pain in IBS by stimulating
sensory nerves.
3 Psychological factors contribute to pain in IBS by promoting
hypervigilance and increasing stress responses.
WHAT IS NEW HERE
3 Pain severity scores correlatedwith daily duration of pain, and
urgency, but not with anxiety, depression, or somatization in
patients with IBS-D.
3 Pain severity scores correlated with biopsy-mediated colonic
afferent firing.
3 Individual biopsymediator levels did not predict pain severity.
TRANSLATIONAL IMPACT
3 Nerve targeting therapies may bemore effective than specific
mediator antagonists.
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